Flower, G., Fritz, H., Balneaves, L.G., Verma, S., Skidmore, B., Fernandes, R., Kennedy, D., Cooley, K., Wong, R., Sagar, S
Anyone whose BMI sits below the threshold, or who doesnt have the qualifying conditions, would be unlikely to receive retatrutide on the NHS in the early years of any rollout, even after approval
This is a game-changer
To learn more about this area of law and how we can put our resources to work for you, give us a call today
Understanding dose equivalence (and why it does not exist) This is the question everyone asks
Finally, the expression of a truncated variant of SSTR5 (SST5TMD4) that shows a preferential intracellular localization but is able to mediate signal transduction (46) has been found to correlate with a reduced ability of octreotide at normalizing hormone secretion in poorly responsive tumors in vivo (47) and with aggressive features, including SS-resistance and tumor invasiveness (48, 49)